Business
Xeris Appoints Anh Nguyen, MD, MBA as Chief Medical Officer
Kenneth Johnson, PharmD, SVP Global Development & Medical Affairs to retire CHICAGO--(BUSINESS WIRE)-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a
About this update from Xeris Biopharma Holdings, Inc.
[{"type":"text","content":"\nKenneth Johnson, PharmD, SVP Global Development & Medical Affairs to retire\n\n\n CHICAGO--(BUSINESS WIRE)--\nXeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that Dr. Anh Nguyen has joined Xeris as Chief Medical Officer (CMO) succeeding Ken Johnson PharmD, SVP, Global Development and Medical Affairs who will retire April 1, 2025. Dr. Nguyen will develop and lead the entire product portfolio vision and strategic direction for the Medical, Regulatory, Preclinical and Clinical Development, and Pharmacovigilance functions, reporting to John Shannon, Xeris’ CEO.\n\n\n“We are pleased to have Anh return to Xeris as our first Chief Medical Officer. Anh is an accomplished clinician-scientist and biopharma executive dedicated to driving advancements in regulatory strategy, clinical development, medical affairs, and commercial launches,” said John Shannon, CEO of Xeris. “He brings his forward-thinking leadership to Xeris at a time when we prepare to embark in our Phase 3 development of XP-8121 and continue to drive growth of our commercial portfolio, especially Recorlev®.”\n\n\nMr. Shannon continued, “We are fortunate that Ken has strategically played an active role in finding his successor and has graciously agreed to help and support in the transition of his organization under the new leadership of Anh. Ken’s guidance and support will undoubtedly ensure a smooth passing of the baton and set the stage for continued success of the entire Medical, Regulatory, Preclinical and Clinical Development, and Pharmacovigilance functions.”\n\n\nDr. Nguyen brings an extensive wealth of clinical and leadership experience to his role as CMO, leading the development of first-in-class therapies including circular RNA-based oncology treatments, gene-edited xenotransplants, immuno-oncology vaccines, and allogeneic CAR-T therapies. Dr. Nguyen served as Vice President and Therapeutic Sector Lead at Asklepios Biopharmaceutical (AskBio), where he directed the IND clearance and early-phase clinical trials of AAV gene therapies for neuromuscular rare disease. Among his many achievements, Dr. Nguyen shaped clinical and regulatory policies for breakthrough therapies while serving as a me...